Immunotherapy: 424 Real Stories

424 stories match immunotherapy. 352 of them mention chemotherapy.

Cancer Stories

Bobbi, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV Colorectal Cancer: Bobbi's Survivor Story

Patient Info: Bobbi Ratliff, 50s | Stage IV

Metastatic Site: liver|lungs

On February 1, 2024, scans showed no evidence of cancer after multimodal treatment for Stage IV disease.

Fight Colorectal Cancer
OutcomeCancer-Free / NED
A patient, who was diagnosed with Colorectal AdenocarcinomaColorectal Cancer

Pembrolizumab enabled complete response and surgery for unresectable dMMR colon cancer

Patient Info: Anonymized, male, 60s

Biomarkers: dMMR/MSI-H; MLH1 loss; PMS2 loss; BRAF mutation; MLH1 promoter hypermethylation

The surgical specimen showed a pathological complete response with no residual cancer and 0 of 43 lymph nodes involved, and follow-up showed no relapse.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Pembrolizumab and surgery for metastatic dMMR colorectal cancer with major response

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: dMMR/MSI-H; MLH1 loss; PMS2 loss; BRAF/RAS wild type; RET::NCOA4 fusion; MLH1 promoter hypermethylation

Metastatic Site: non-regional lymph nodes

Surgery showed a major pathological response with less than 10% viable tumor. Pembrolizumab was restarted after surgery, and no relapse had been documented.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Pembrolizumab led to complete response before surgery for metastatic dMMR colon cancer

Patient Info: Anonymized, male, 70+ | Stage IV

Biomarkers: dMMR/MSI-H; MLH1 loss; PMS2 loss; BRAF mutation; heterozygous MUTYH p. pathogenic variant

Metastatic Site: liver

The 2023 liver resection showed a pathological complete response with no residual tumor, and he entered follow-up without additional therapy.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Colorectal AdenocarcinomaColorectal Cancer

Pembrolizumab produced a complete response in unresectable dMMR colon cancer

Patient Info: Anonymized, female, 70+

Biomarkers: dMMR/MSI-H; MLH1 loss; MSH2 loss; RAS/BRAF wild type; MLH1 promoter hypermethylation

Surgery found a pathological complete response with no residual cancer in the colon or 58 lymph nodes, and follow-up showed no relapse.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV enteric-type lung adenocarcinoma with EGFR mutations and MSI-high disease

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M; MSI-high; high tumor mutation burden; MLH1 mutation; pMMR; PD-L1-negative

Metastatic Site: lung, pleura

The cancer progressed through multiple targeted, chemotherapy, and immunotherapy regimens. He died about 30 months after the initial diagnosis.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Rare lung cancer first discovered as a mass in the skull

Patient Info: Anonymized, Male | Stage IV

Biomarkers: KRAS ; CK7-positive; CDX2-positive; pathology favoured pulmonary enteric adenocarcinoma

Metastatic Site: skull base / sphenoid sinus; right posterior acetabulum

He received palliative radiation and prolonged systemic therapy, completing 35 cycles including 31 maintenance cycles of pemetrexed and pembrolizumab.

PubMed Central
OutcomeNot reported
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Metastatic gastric cancer with an ATM mutation responding to olaparib

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: Pathogenic germline ATM mutation, HER2-negative, PD-L1 15%

Metastatic Site: peritoneum

He had a deep response lasting about 18 months, but imaging in December 2023 again showed peritoneal carcinomatosis.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Colorectal AdenocarcinomaColorectal Cancer

Colorectal cancer: using a blood test (ctDNA) to guide immunotherapy after surgery — Case 1

Patient Info: Anonymized, Male, 50s

Biomarkers: KRAS ; TMB 11 mutations/Mb; loss of MLH1 and PMS2; dMMR/MSI-H; germline multigene panel negative; ctDNA positive after surgery and chemotherapy

Pembrolizumab cleared ctDNA within about 3 months. After completing 1 year of immunotherapy, surveillance CT showed no evidence of disease and ctDNA remained negative.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Colorectal AdenocarcinomaColorectal Cancer

Colorectal cancer: using a blood test (ctDNA) to guide immunotherapy after surgery

Patient Info: Anonymized, Male, 40s

Biomarkers: dMMR/MSI-H; pathogenic germline MLH1 c.1459C>T consistent with Lynch syndrome; postoperative ctDNA rose during chemotherapy and became near-undetectable on pembrolizumab

He continued pembrolizumab with no evidence of disease on interval CT and near-undetectable ctDNA. Grade 1 thyroiditis was monitored without treatment interruption.

PubMed Central
OutcomeIn Treatment
Jeff, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV Colorectal Cancer: Jeff's Patient Story

Patient Info: Jeff Williams, Male, 50s | Stage IV

Metastatic Site: Liver; lungs

As of December 2023, Jeff was living with recurrent Stage IV colorectal cancer, had recently developed more lung tumors, continued chemotherapy locally every 2 weeks, and returned to UT MD Anderson every 3 months for scans.

MD Anderson
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Treatment-Refractory Triple-Negative Breast Cancer Treated With Tumor-Infiltrating Lymphocytes

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: Germline BRCA1 pathogenic variant; later triple-negative phenotype

Metastatic Site: skin, lungs, bones

Tumor burden briefly decreased after tumor-infiltrating lymphocyte therapy, but she developed severe treatment complications followed by rapid cancer relapse and died about 1 month after the TIL/IL-2 treatment began.

PubMed Central
OutcomeIn Memory
Dania, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV Colorectal Cancer: Dania's Patient Story

Patient Info: Dania, Female, Under 40 | Stage IV

Biomarkers: Not reported; pathology supported Keytruda eligibility

Metastatic Site: Liver; peritoneum

As of December 2023, Dania had Stage IV colon cancer but described an excellent response to Keytruda, successful colon/hernia surgery, and successful liver surgery while still healing and continuing follow-up.

The Patient Story
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Brain radiation therapy complication (radionecrosis) potentially linked to combined chemo-immunotherapy

Patient Info: Anonymized, Female | Stage IV

Biomarkers: PD-L1 0%; tumour mutational burden 33 mutations/Mb; TP53 mutation at diagnosis; later ctDNA included KEAP1 and NOTCH3 alterations

Metastatic Site: brain; presumed leptomeningeal disease

She recovered completely from surgery for radiation necrosis, resumed cancer treatment and remained neurologically intact at 18 months. She was found deceased 9 months later; the cause of death was unknown.

PubMed Central
OutcomeIn Memory